AOP Orphan strengthens core CNS specialty business with high promise in movement disorder treatments
19 June 2015 | By AOP Orphan Pharmaceuticals AG
AOP Orphan Pharmaceuticals AG has announced the regulatory submission of Tetrabenazine for the treatment of tardive dyskinesia in a DCP (decentralized procedure) for several European countries with UK being reference member state...